It includes a safety in [challenge] in vivo, to satisfy the request, such as organ selectivity and cancer cells and relaxivity, is to provide a molecular aggregates and porphyrin novel metal complexes can be applied to MRI contrast agent. Porphyrin metal complex represented by [SOLUTION] Formula (1) {Wherein, R 12 through R 1 is, having 1 to 10 carbon atoms which may have a hydrogen atom, a halogen atom, a nitro group, a cyano group, a sulfonyl group, a hydroxy group, an amino group, a carboxyl group, a substituent which may have a cycloalkyl group having 6 alkyl group, carbon atoms 3, an alkoxy group having 1 to 6 carbon atoms, a substituted phenyl group or the formula (2) (N is. Representing the 1-10) (However, having a group represented by the formula (2) is at least one of R 12 to R 1) represents, M group selected from the group consisting of oligo ethylene glycol methyl ether group represented by the I represents a trivalent metal atom and 5 valence which may have a substituent or a substituted atom or a divalent metal atom. }. [Selection Figure Figure 2【課題】生体内での安全性を備え、緩和能やガン細胞や臓器選択性などの要求を満足する、MRI造影剤に応用できる新規なポルフィリン金属錯体及びその分子集合体を提供すること。【解決手段】式(1)で表されるポルフィリン金属錯体{式中、R1乃至R12は、水素原子、ハロゲン原子、ニトロ基、シアノ基、スルホニル基、ヒドロキシ基、アミノ基、カルボキシル基、置換基を有してもよい炭素原子数1乃至10のアルキル基、炭素原子数3乃至6のシクロアルキル基、炭素原子数1乃至6のアルコキシ基、置換基を有してもよいフェニル基又は式(2)(nは1から10を表す。)で表されるオリゴエチレングリコールメチルエーテル基からなる群から選択される基(ただし、R1乃至R12のうち少なくとも一つは上記式(2)で表される基を有する)を表し、Mは、2価の金属原子又は置換原子若しくは置換基を有してもよい3価~5価の金属原子を表す。}。【選択図】図2
